Compare Albemarle Corp. (ALB) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs Oscar Health Inc — how do they compare? Albemarle Corp. trades at $128.07 (market cap $15.27B), while Oscar Health Inc trades at $29.57 (market cap $8.63B). The key difference: Albemarle Corp. is the larger of the two by market cap, and Albemarle Corp. pays a 1.27% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| ALB | OSCR | |
|---|---|---|
Market Cap | $15.27B | $8.63B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $32.18 |
52-Week Low | $72.58 | $10.85 |
Enterprise Value | $17.75B | $4.99B |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) trades at $128.29, down 2.23% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company reported strong Q2 2026 results with EPS of $3.75 beating estimates by 17%, driven by improved lithium pricing and specialty chemicals performance. Despite recent profitability challenges with negative net income in 2025, cash flow generation remains healthy at $1.28B from operations.
Analyst consensus leans positive with 42% buy ratings and $184.50 price target representing 44% upside potential. Key risks include lithium price volatility and Q3 margin pressure, while catalysts include sustained demand for energy storage solutions and ongoing balance sheet improvements through debt reduction.
Oscar Health (OSCR) trades at $29.11, up 5.2% with strong recent earnings momentum, beating estimates in Q1 and Q2 2026. The stock shows bearish technical signals but benefits from record profitability and raised 2026 guidance. Revenue surged 70% to $4.9 billion in H1 2026, with net income turning positive at $551 million versus a 2025 loss. Valuation remains attractive with P/S of 0.53, suggesting potential undervaluation versus sector peers.
Outlook is positive given membership growth and cost discipline, but risks include medical cost volatility and competitive pressures. Analyst consensus price target of $32.50 implies 12% upside, though technical resistance near $30 may limit near-term gains. Execution on guidance and sustained margin expansion are key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
